Overactive Bladder Treatment Market Expected to Reach $3.5 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Overactive Bladder Treatment Market," The overactive bladder treatment market size was valued at $2.4 billion in 2021, and is estimated to reach $3.5 billion by 2031, growing at a CAGR of 3.6% from 2022 to 2031.

The overactive bladder treatment market trends that drive the growth of the market include an increase in incidences of overactive bladder. For instance, according to Hartford HealthCare, a Tallwood Urology and Kidney Institute, overactive bladder affects about 33 million American men and women every year. This number is expected to be greater as people living with overactive bladder do not seek help as it seems to be embarrassing. Overactive bladder is mainly caused due to factors such as involuntary contraction of the bladder muscles, neurological disorders such as stroke and multiple sclerosis, diabetes, urinary tract infections, abnormalities in the bladder such as tumors or bladder stones and others. Thus, rise in incidences of overactive bladder in population around the globe increases the demand for overactive bladder treatment medications, which propels the growth of overactive bladder treatment market size.

Overactive bladder can also be caused due to conditions affecting the nervous system. People having previous operations for stress incontinence are more likely to have OAB. In addition, the amount and type of liquid intake also contribute to OAB symptoms. For instance, caffeinated drinks and alcoholism significantly contribute to increase the overactive bladder symptoms. Furthermore, the increase in geriatric population also drives the market growth. As geriatric population are more prone to conditions such as neurological impairment, kidney, diabetes and others, there is a huge chance of rising incidences of overactive bladder in geriatric population. This augments the growth during overactive bladder treatment market analysis. 

In addition, an increase in R&D activities in pharmaceutical fields around the globe is also anticipated to drive the market during the forecast period. The key market players are focusing on R&D activities to develop drug molecules that are highly efficient and have greater results in the patients. In addition, the key market players have also adopted various strategies such as product launch and product approvals which offer lucrative opportunities for the growth of the overactive bladder treatment market. For instance, Urovant Sciences, a company owned by Sumitovant Biopharma is developing a product having active ingredient Vibegron for the treatment of overactive bladder in men with benign prostatic hyperplasia (BPH). Thus, such product development and increasing R&D activities are anticipated to boost the market during the overactive bladder treatment market forecast.

Moreover, key players from the developed regions are focusing on investment in developing regions owing to the presence of resources for manufacturing and lesser investment cost as compared to developed regions. This is also anticipated to expand the market during the forecast period.On the basis of drug class, the market is classified into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox and others. The beta-3 adrenergic drugs segment was the largest overactive bladder treatment market share contributor to the market in 2021, owing to the surge in demand for beta-3 adrenergic drugs in treatment of OAB. 

The anticholinergics segment is anticipated to grow at a fastest rate during the forecast period, owing to the increase in incidences of overactive bladder, increase in awareness among the population regarding urological conditions such as overactive bladder and others. On the basis of disease type, the market is classified into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment dominated the market in 2021, which was attributed to increased incidences of idiopathic overactive bladder and rise in awareness among people about the condition and treatment options. On the other hand, the neurogenic overactive bladder segment is anticipated to grow at the highest rate during the forecast period, owing to technological advances in the treatment of OAB.

On the basis of distribution channel, the market is segmented into hospital pharmacies, online providers and drug stores and retail pharmacies. The drug stores and retail pharmacies exhibited the highest growth in 2021, owing to the increase in number of drug stores and pharmacies around the globe, and due to easy availability of OAB medications in the drug store. On the other hand, the online providers segment is anticipated to grow at the fastest rate owing to easy accessibility of medications and doors step delivery services. In addition, the pandemic has created many shifts in consumer behavior, and one of the most impactful changes is the buying drugs from e-commerce websites, which is also anticipated to boost the segment growth. 

Region wise, North America obtained the highest overactive bladder treatment market share in 2021, owing to the rise in incidences of overactive bladder condition due to increase in prevalence of conditions such as diabetes, kidney disorders, neurological disorders and others. On the other hand, Asia-Pacific is expected to witness highest growth during the forecast period, owing to factors such as rise in investments in manufacturing of high-quality products by major key players, and availability of raw materials for manufacturing of overactive bladder treatment medications.

Key findings of the study
• By drug class, the beta-3 adrenergic drugs segment was the highest contributor to the overactive bladder treatment industry in 2021.
• By application, idiopathic overactive bladder segment dominated the market in 2021 and neurogenic overactive bladder is anticipated to grow at the highest CAGR during the forecast period.
• By distribution channel, the drug store and retail pharmacies dominated the overactive bladder treatment industry in 2021 and online providers segment is anticipated to grow at a fastest rate during the forecast period.
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.